Bicyclic compounds as nr2b receptor antagonists

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 235/12 (2006.01) A61K 31/404 (2006.01) A61K 31/416 (2006.01) A61K 31/4184 (2006.01) A61K 31/423 (2006.01) A61K 31/47 (2006.01) A61K 31/517 (2006.01) A61P 25/00 (2006.01) C07D 209/08 (2006.01) C07D 215/12 (2006.01) C07D 215/26 (2006.01) C07D 231/56 (2006.01) C07D 235/08 (2006.01) C07D 239/94 (2006.01) C07D 263/56 (2006.01)

Patent

CA 2521907

This invention provides a compound of the formula (I) wherein R1 and R2 independently represent a hydrogen atom or the like; X represents a covalent bond or the like: A represents a bicyclic, aromatic, saturated or partially unsaturated heterocyclic or carbocyclic group having from 8 to 12 ring atoms; or the like: B represents a phenyl group or a heteroaryl group having from 5 to 6 ring atoms or the like: These compounds are useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

L'invention concerne un composé de formule (I), dans laquelle R?1¿ et R?2¿ représentent indépendamment l'un de l'autre un atome d'hydrogène ou similaire, X représente une liaison covalente ou similaire, A représente un groupe hétérocyclique ou carbocyclique bicyclique, aromatique, saturé ou partiellement insaturé avec 8 à 12 atomes cycliques, ou similaires, et B représente un groupe phényle ou un groupe hétéroaryle avec 5 à 6 atomes cycliques, ou similaires. Ces composés sont utiles pour traiter des états pathologiques causés par une suractivation du récepteur NMDA NR2B, tels que des algies ou similaires chez des mammifères. L'invention concerne également une composition pharmaceutique qui contient ce composé.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Bicyclic compounds as nr2b receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic compounds as nr2b receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic compounds as nr2b receptor antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1533027

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.